{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:14:13Z","timestamp":1793060053658,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jhep.2015.12.018","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T07:30:48Z","timestamp":1451374248000},"page":"1011-1019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)"],"prefix":"10.1016","volume":"64","author":[{"given":"Henry L.Y.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Tsung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla S.","family":"Coffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng Gee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Marcellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Serfaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Critelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Wind-Rotolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.12.018_b0005","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.12.018_b0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"2","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2015.12.018_b0015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.12.018_b0020","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.12.018_b0025","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.12.018_b0030","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.gastro.2010.03.059","article-title":"Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B","volume":"139","author":"Reijnders","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.12.018_b0035","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.52.3.420","article-title":"Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase","volume":"52","author":"van Nunen","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.12.018_b0040","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.12.018_b0045","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.12.018_b0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.12.018_b0055","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Trepo","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.12.018_b0060","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.virol.2010.02.022","article-title":"Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities","volume":"401","author":"Pagliaccetti","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2015.12.018_b0065","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1128\/JVI.79.6.3851-3854.2005","article-title":"Lambda interferon inhibits hepatitis B and C virus replication","volume":"79","author":"Robek","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2015.12.018_b0070","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cytogfr.2003.10.001","article-title":"The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions","volume":"15","author":"Langer","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jhep.2015.12.018_b0075","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.coi.2011.07.007","article-title":"IFN-lambdas","volume":"23","author":"Kotenko","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jhep.2015.12.018_b0080","doi-asserted-by":"crossref","first-page":"349575","DOI":"10.1155\/2011\/349575","article-title":"Interferon lambda: a new sword in cancer immunotherapy","volume":"2011","author":"Lasfar","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.jhep.2015.12.018_b0085","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.4049\/jimmunol.1102038","article-title":"Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells","volume":"189","author":"Yin","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2015.12.018_b0090","doi-asserted-by":"crossref","first-page":"7749","DOI":"10.1128\/JVI.02438-06","article-title":"Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases","volume":"81","author":"Zhou","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2015.12.018_b0095","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.21312","article-title":"Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes","volume":"44","author":"Doyle","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.12.018_b0100","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1089\/jir.2010.0066","article-title":"Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C","volume":"30","author":"Ramos","year":"2010","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jhep.2015.12.018_b0105","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1053\/j.gastro.2006.09.052","article-title":"Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics","volume":"131","author":"Marcello","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.12.018_b0110","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4161\/cbt.7.7.6192","article-title":"IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK\/STAT signaling activity","volume":"7","author":"Maher","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jhep.2015.12.018_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022200","article-title":"USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response","volume":"6","author":"Francois-Newton","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2015.12.018_b0120","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jhep.2014.07.022","article-title":"A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection","volume":"61","author":"Muir","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.12.018_b0125","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.12.018_b0130","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"10","author":"Cooksley","year":"2003","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.12.018_b0135","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-119-4-199308150-00011","article-title":"Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis","volume":"119","author":"Wong","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2015.12.018_b0140","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1365-2893.2012.01610.x","article-title":"Distinct and overlapping genomic profiles and antiviral effects of Interferon-lambda and -alpha on HCV-infected and noninfected hepatoma cells","volume":"19","author":"Kohli","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.12.018_b0145","article-title":"IFN-lambda-mediated IL-12 production in macrophages induces IFN-gamma production in human NK cells","author":"de Groen","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jhep.2015.12.018_b0150","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1084\/jem.20131557","article-title":"IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies","volume":"211","author":"Duong","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2015.12.018_b0155","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.coviro.2011.11.001","article-title":"Induction and function of type I and III interferon in response to viral infection","volume":"1","author":"Levy","year":"2011","journal-title":"Curr Opin Virol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815008594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815008594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T16:22:05Z","timestamp":1668615725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815008594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0168827815008594"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.12.018","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}